Does pharmacologic reduction of Lp(a) concentration decrease CAD risk without increasing T2D risk?
Pharmacologic reduction of Lp(a) concentration
Risk of cardiovascular diseases (CAD) and Type 2 Diabetes (T2D)hard clinical
Pharmacologic reduction of high Lp(a) to median levels is predicted to lower CAD risk without the adverse effect of increasing T2D risk seen at very low Lp(a) levels.
Molar concentration is the attribute of Lp(a) that affects risk of cardiovascular diseases. Low Lp(a) concentration (bottom 10%) increases T2D risk. Pharmacologic reduction of Lp(a) concentration in the 20% of individuals with the greatest concentration down to the population median is predicted to decrease CAD risk without increasing T2D risk.
Building similarity graph...
Analyzing shared references across papers
Loading...
Daníel F. Guðbjartsson
Guðmundur Þorgeirsson
Patrick Sulem
Journal of the American College of Cardiology
University of Iceland
National University Hospital of Iceland
deCODE Genetics (Iceland)
Building similarity graph...
Analyzing shared references across papers
Loading...
Guðbjartsson et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69d8f3e71ab91f1400bedc7b — DOI: https://doi.org/10.1016/j.jacc.2019.10.019
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: